COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity
Our results demonstrate that COVID-19 suppresses the immune activity and consequentially elevates the level of BCR-ABL P210 of CML patients.
Authors
- Wancheng Liu (ORCID: https://orcid.org/0000-0002-7628-0323)
- Jinting Liu (ORCID: https://orcid.org/0000-0003-2136-8560)
- Daoxin Ma (ORCID: https://orcid.org/0000-0003-0664-8441)
- Guosheng Li (ORCID: https://orcid.org/0000-0001-5193-5488)
- Ruifeng Tian
- Na He (ORCID: https://orcid.org/0000-0002-1571-0748)
Institutions
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1452035
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China